Fumarranol is a drug which acts as an inhibitor of the type 2 methionine aminopeptidase enzyme METAP2. It was derived by structural modification of the natural product fumagillin. It was originally developed as an anti-angiogenesis drug for the treatment of cancer,[1] but it was subsequently found to bind with high affinity to the METAP2 enzyme in malaria parasites and has been investigated as a potential treatment for malaria.[2][3]
^Lu J, Chong CR, Hu X, Liu JO (September 2006). "Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo". Journal of Medicinal Chemistry. 49 (19): 5645–8. doi:10.1021/jm060559v. PMID 16970390.
^Chen X, Xie S, Bhat S, Kumar N, Shapiro TA, Liu JO (February 2009). "Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo". Chemistry & Biology. 16 (2): 193–202. doi:10.1016/j.chembiol.2009.01.006. PMID 19246010.
^Deu E (August 2017). "Proteases as antimalarial targets: strategies for genetic, chemical, and therapeutic validation". The FEBS Journal. 284 (16): 2604–2628. doi:10.1111/febs.14130. PMC 5575534. PMID 28599096.
Fumarranol is a drug which acts as an inhibitor of the type 2 methionine aminopeptidase enzyme METAP2. It was derived by structural modification of the...
mass: 280.36 g/mol, exact mass: 280.1675 u) may refer to: Brefeldin A Fumarranol This set index page lists chemical structure articles associated with...
Bhat S, Kumar N, Shapiro TA, Liu JO (February 2009). "Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria...
shown to possess antimalarial activity both in vitro and in vivo, and fumarranol, another fumagillin analog, represents a promising lead. The fumagillin-derived...